Results 231 to 240 of about 571,284 (260)

Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database

Multiple Sclerosis Journal, 2021
Olaf Stuve, Amber Salter, Natalia Gonzalez Caldito   +2 more
exaly  

Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials

Clinical Trials, 2021
Leonard Saltz, Romain Cohen, Qian Shi
exaly  

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Zou Fan, Cui Zhiwei, Lou Siyu
exaly  

New Frontiers in Patient-Reported Outcomes: Adverse Event Reporting, Comparative Effectiveness, and Quality Assessment

Annual Review of Medicine, 2014
Ethan Basch
exaly  

Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice Committee

Journal of Vascular and Interventional Radiology, 2017
Sanjay Misra, Bairbre Connolly, Christopher Morris   +2 more
exaly  

Safety and adverse event profile of duloxetine

Expert Opinion on Drug Safety, 2005
Joachim Wernicke, Ilker Yalcin
exaly  

Descriptive epidemiology of adverse events after immunization: Reports to the Vaccine Adverse Event Reporting System (VAERS), 1991-1994

Journal of Pediatrics, 1997
M M Braun
exaly  

Adverse Events

2014
Marybeth Whitney, Flora M. Hammond
openaire   +1 more source

Crizotinib-induced esophageal ulceration: A novel adverse event of crizotinib

Lung Cancer, 2013
Susumu Hijioka, Toyoaki Hida, Yoshitsugu Horio   +2 more
exaly  

Drug-versus-Drug Adverse Event Rate Comparisons

Drug Safety, 2012
Ronald K Pearson
exaly